Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MGEN

Miragen Therapeutics (MGEN) Stock Price, News & Analysis

Miragen Therapeutics logo

About Miragen Therapeutics Stock (NASDAQ:MGEN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$12.32
$13.29
50-Day Range
$14.34
$23.01
52-Week Range
$4.66
$34.05
Volume
1.03 million shs
Average Volume
134,027 shs
Market Capitalization
$51.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Remove Ads
Receive MGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGEN Stock News Headlines

DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Viridian Therapeutics Inc (VRDN)
See More Headlines

MGEN Stock Analysis - Frequently Asked Questions

Miragen Therapeutics, Inc. (NASDAQ:MGEN) issued its quarterly earnings data on Tuesday, November, 10th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.03. Miragen Therapeutics had a negative trailing twelve-month return on equity of 141.66% and a negative net margin of 1,393.50%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Miragen Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Nokia Oyj (NOK), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX) and Pfizer (PFE).

Company Calendar

Last Earnings
11/10/2020
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:MGEN
Fax
N/A
Employees
45
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-41,870,000.00
Net Margins
-1,393.50%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.46 million
Price / Cash Flow
N/A
Book Value
$6.78 per share
Price / Book
1.93

Miscellaneous

Free Float
N/A
Market Cap
$51.08 million
Optionable
Not Optionable
Beta
1.66
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:MGEN) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners